Dianthus Therapeutics ( NASDAQ:DNTH ) Full Year 2024 Results Key Financial Results Net loss: US$85.0m (loss widened by... Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG ...
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback